Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 1/20 | 0.52 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.52 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416971 | 1.00 | MAPT (0.64) | MAPTKDM4ETP53MAPK1HPGD | |
| Syringol SCHEMBL156388 | 0.83 | KDM4E (0.80) | MAPTKDM4ETP53MAPK1HPGD | |
| Syringol SCHEMBL7610366 | 0.80 | KDM4E (0.76) | MAPTKDM4ETP53MAPK1HPGD | |
| Syringol SCHEMBL6049240 | 0.80 | KDM4E (0.76) | MAPTKDM4ETP53MAPK1HPGD | |
| Syringol SCHEMBL8986496 | 0.80 | KDM4E (0.76) | MAPTKDM4ETP53MAPK1HPGD | |
| SCHEMBL30417463 | 0.79 | PTPN1 (0.41) | MAPTKDM4ETP53MAPK1HPGD | |
| SCHEMBL21262585 | 0.79 | PTPN1 (0.41) | MAPTKDM4ETP53MAPK1HPGD | |
| SCHEMBL4015318 | 0.78 | L3MBTL1 (0.56) | MAPTKDM4EHPGDALOX15ALDH1A1 | |
| 3-Methoxycatechol SCHEMBL67332 | 0.78 | TP53 (1.00) | MAPTKDM4ETP53MAPK1HPGD | |
| 3-Methoxycatechol SCHEMBL29477155 | 0.78 | TP53 (1.00) | MAPTKDM4ETP53MAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462433-B2 | Undercoat layer containing charge transfer molecule, andTiO2; imaging layer; charge transfer molecule complexes with the TiO2 to form coordination bonds and the coordination bonds provide a reduction in ghosting; electrophotographic imaging members; improved image quality | XEROX CORPORATION (US) | 2008-12-09 | — | — | US | claimed |
| US-20070048639-A1 | Undercoat layer containing charge transfer molecule, andTiO2; imaging layer; charge transfer molecule complexes with the TiO2 to form coordination bonds and the coordination bonds provide a reduction in ghosting; electrophotographic imaging members; improved image quality | XEROX CORPORATION (US) | 2007-03-01 | — | — | US | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-4855476-A | 3,4-DIBENZYLOXY-5-FLUOROBENZYLCYANIDE FROM 2-FLUORO-6-METHOXYP HENOL | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1989-08-08 | — | — | US | claimed |
| WO-2025245367-A1 | INHIBITING CATECHOL-O-METHYLTRANSFERASE (COMT) | PSY THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| CN-116234550-B | Aromatic formyl substituted tricyclic compound and preparation method and application thereof | 劲方医药科技(上海)股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240360154-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG GENFLEET THERAPEUTICS CO., LTD. (CN) | 2024-10-31 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| CN-113637005-B | KRAS inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4063358-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4223753-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2023-08-09 | — | — | EP | disclosed |
| EP-0658543-A1 | PROCESS FOR PRODUCING $g(a)-ALKOXYIMINOPHENYLACETONITRILE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1995-06-21 | — | — | EP | disclosed |
| EP-0609885-A1 | Acridinium compounds and conjugates thereof | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-10 | — | — | EP | disclosed |
| US-4855476-A | 3,4-DIBENZYLOXY-5-FLUOROBENZYLCYANIDE FROM 2-FLUORO-6-METHOXYP HENOL | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1989-08-08 | — | — | US | disclosed |
| US-4737504-A | INCREASE BETA-2 ADRENERGIC ACTIVITY WHILE DECREASING BETA-1; CARDIOVASCULAR AND RESPIRATORY DISORDERS | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1988-04-12 | — | — | US | disclosed |
| EP-0080012-A1 | 6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-01 | — | — | EP | disclosed |
| EP-0007070-B1 | 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS HAVING DOPAMINE RECEPTOR BLOCKING ACTIVITY | SMITHKLINE BECKMAN CORPORATION (US) | 1983-01-19 | — | — | EP | disclosed |
| US-4265890-A | ANTIPSYCHOTIC, ANTIEMETICS | SMITHKLINE CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| EP-0007070-A1 | 2,3,4,5-Tetrahydro-1H-3-Benzazepines, process for their production and pharmaceutical compositions having dopamine receptor blocking activity | SMITHKLINE BECKMAN CORPORATION (US) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | MAPT 506/4885KDM4E 4664/4885TP53 3310/4885 |
| US-20240360154-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | BTK, WEE1, WEE2 | MAPT 4672/4885KDM4E 1724/4885TP53 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.